Scarica l'app Stockscreener
20.53
8.43%
-1.9393
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Some 13 years and $2 billion later, Denali Therapeutics wins first drug approval - The Business Journals
FDA approves drug to treat neurologic manifestations of Hunter syndrome - The Pharma Letter
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - BioSpace
Denali approval revives surrogate-endpoint path in neuronal MPS - BioCentury
Stifel raises Denali Therapeutics price target on drug approval - Investing.com
Goldman Sachs raises Denali Therapeutics stock price target on FDA approval - Investing.com
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost - Yahoo Finance
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah - BioWorld MedTech
BTIG raises Denali Therapeutics price target to $38 on drug approval - Investing.com Canada
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy - TipRanks
FDA clears Denali (NASDAQ: DNLI) AVLAYAH therapy for Hunter syndrome - Stock Titan
FDA approves Denali’s Hunter syndrome brain therapy AVLAYAH By Investing.com - Investing.com India
FDA approves Denali Therapeutics drug for Hunter syndrome - statnews.com
Oppenheimer raises Denali Therapeutics price target on FDA approval - Investing.com
Denali Therapeutics Inc. announced that its new drug Avlayah will soon be available on the US market after receiving regulatory approval. - Bitget
Denali Therapeutics announces U.S. FDA approval of Avlayah(TM) (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) - marketscreener.com
Denali Therapeutics Announces U.S. FDA Approval Of Avlayah™ (Tividenofusp Alfa-Eknm) For Treatment Of Hunter Syndrome (Mps Ii) - TradingView
Denali Therapeutics (NASDAQ:DNLI) Shares Gap UpStill a Buy? - MarketBeat
US FDA approves Denali's genetic disorder therapy for children - Reuters
Gap Down: Is Denali Therapeutics Inc on track to beat earningsEarnings Trend Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Denali stock gains on FDA nod for lead asset (DNLI:NASDAQ) - Seeking Alpha
Bearish Setup: Why is Denali Therapeutics Inc stock going downQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
Published on: 2026-03-22 06:29:27 - baoquankhu1.vn
Aug Shorts: Can Denali Therapeutics Inc withstand a market correction2026 Retail & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart.com
EV Market: How sensitive is Denali Therapeutics Inc to inflationProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts - MarketBeat
Transcript : Denali Therapeutics Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 03 - marketscreener.com
Price-Driven Insight from (DNLI) for Rule-Based Strategy - Stock Traders Daily
Pharma News: Is Denali Therapeutics Inc stock suitable for long term investing2026 Levels & Weekly Stock Breakout Alerts - baoquankhu1.vn
Holocene Advisors LP Grows Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
1,000,000 Shares in Denali Therapeutics Inc. $DNLI Purchased by Foresite Capital Management VI LLC - MarketBeat
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection - BioSpace
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build - MarketBeat
250,000 Shares in Denali Therapeutics Inc. $DNLI Bought by Boxer Capital Management LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA) - The Globe and Mail
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? - Yahoo Finance
DNLI News & Events - Intellectia AI
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance
Denali Rises 11.8% Over the Past Month: Should You Buy, Sell, or Keep the Stock? - Bitget
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock? - TradingView
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration - Sahm
Denali ‘Moving In A Positive Direction’ With FDA Toward Hunter Drug Action Date - Citeline News & Insights
DNLI: Awaiting FDA decision on a novel Hunter syndrome therapy, with broad pipeline and commercial momentum - TradingView
DNLI: Imminent FDA decision and expanding pipeline highlight strong clinical and commercial momentum - TradingView
Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.1%Should You Buy? - MarketBeat
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
How Denali Therapeutics Inc. stock reacts to global recession fearsPortfolio Risk Report & Stock Market Timing Techniques - Naître et grandir
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - MSN
(DNLI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Denali Therapeutics (DNLI) Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed? - simplywall.st
HC Wainwright Issues Positive Forecast for DNLI Earnings - MarketBeat
Rafferty Asset Management LLC Buys 60,624 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Market Wrap: Can Denali Therapeutics Inc scale operations efficientlyJuly 2025 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn
DNLI: Pivotal 2026 ahead with FDA review, new launches, and major clinical milestones in rare diseases - TradingView
TD Asset Management Inc Trims Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):